Al's Comment:
The news here is the upgrade from NCCN's Category 2b "Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate" to 2a "Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate".   The difference is that previously most (over 50%) of the doctors on the committee agreed that Optune is appropriate as a standard treatment options to use for Glioblastoma. Now over 85% of the doctors say it is appropriate.    
 


Posted on: 07/20/2022

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click HERE to read it!